TABLE 2.
Population | Nb of carriers | OR (95% CI) | p Value b |
---|---|---|---|
Patients c (n = 3322) | 8 (0.24%) | 11.39 (5.103–28.93) | <0.0001 |
Controls (non‐cancer, NFE) d (n = 59 095) | 12 (0.020%) |
LoF AXIN2 variants include stop‐gain, frameshift, canonical splice‐site, and start‐loss variants.
Frequencies between groups were compared using Fisher's exact test. Associated ORs were calculated for each group.
Only patients tested in consecutive series were considered (Figure 1).
Control population data were obtained from gnomAD v2.1 (non‐cancer, non‐Finnish European individuals).